Autopsy report · NCT05860296

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

“Lack of efficacy and enrollment challenges”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 6 months before it stopped.
• 36 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

SignalChem Lifesciences Corporation

Sponsor type

Industry

Conditions

Lung Cancer, Nonsmall Cell; Lung Cancer Stage IV; Lung Cancer Metastatic

Interventions

SLC-391; pembrolizumab

Participants

36

Sites

12

Countries

Canada, United States

Trials that died the same way

• Quality of Life Outcomes in Spinal Cord Stimulation
  “Inadequate enrollment” (80% match in meaning)
• 30 Day Rehospitalization Risk in Hemodialysis Patients
  “Lack of enrollment as expected” (80% match in meaning)
• A Post Market Study on DRG Stimulation in FBSS (SYMPATHY)
  “Lack of enrollments” (80% match in meaning)
• Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
  “Lack of substantial enrollment” (80% match in meaning)
• Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
  “lack of efficacy and lack of funding” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.